Vaccine

UK Prime Minister Meets the Team Behind the UK's Vaccines Manufacturing and Innovation Centre

Friday, September 18, 2020 - 11:21pm

HARWELL, England, Sept. 18, 2020 /PRNewswire/ -- UK Prime Minister Boris Johnson today visited the construction site of the rapidly developing UK's Vaccines Manufacturing and Innovation Centre (VMIC) at Harwell Science and Innovation Campus.

Key Points: 
  • HARWELL, England, Sept. 18, 2020 /PRNewswire/ -- UK Prime Minister Boris Johnson today visited the construction site of the rapidly developing UK's Vaccines Manufacturing and Innovation Centre (VMIC) at Harwell Science and Innovation Campus.
  • Prime Minister Boris Johnson, said:"Brilliant scientists in Oxfordshire and around the UK are driving global efforts to develop a safe vaccine that works to defeat coronavirus.
  • "That is why construction of the Vaccine Manufacturing and Innovation Centre at Harwell, backed by 158 million from the Government, is fully underway in Oxfordshire.
  • Dr Matthew Duchars, CEO of The Vaccines Manufacturing and Innovation Centresaid: "Today's visit from the Prime Minister is testament to the incredible work being carried out by an exceptional team at VMIC and amongst our partners.

UK Prime Minister Meets the Team Behind the UK's Vaccines Manufacturing and Innovation Centre

Friday, September 18, 2020 - 11:18pm

HARWELL, England, Sept. 18, 2020 /PRNewswire/ -- UK Prime Minister Boris Johnson today visited the construction site of the rapidly developing UK's Vaccines Manufacturing and Innovation Centre (VMIC) at Harwell Science and Innovation Campus.

Key Points: 
  • HARWELL, England, Sept. 18, 2020 /PRNewswire/ -- UK Prime Minister Boris Johnson today visited the construction site of the rapidly developing UK's Vaccines Manufacturing and Innovation Centre (VMIC) at Harwell Science and Innovation Campus.
  • Prime Minister Boris Johnson, said:"Brilliant scientists in Oxfordshire and around the UK are driving global efforts to develop a safe vaccine that works to defeat coronavirus.
  • "That is why construction of the Vaccine Manufacturing and Innovation Centre at Harwell, backed by 158 million from the Government, is fully underway in Oxfordshire.
  • Dr Matthew Duchars, CEO of The Vaccines Manufacturing and Innovation Centresaid: "Today's visit from the Prime Minister is testament to the incredible work being carried out by an exceptional team at VMIC and amongst our partners.

Worldwide Cancer Vaccines Industry to 2025 - Analysis of Promising Vaccines

Friday, September 18, 2020 - 8:00pm

This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.

Key Points: 
  • This report provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market.
  • The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market.
  • The report presents a clear perception of current and future developments of the global cancer vaccines market.
  • The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 2:00pm

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Axon Neuroscience to launch world's first crowdfunded vaccine against COVID-19

Friday, September 18, 2020 - 11:54am

BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.

Key Points: 
  • BRATISLAVA, Slovakia, Sept. 18, 2020 /PRNewswire/ -- AXON Neuroscience ("Axon"), a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases with a unique peptide vaccine platform, is launching the world's first independently-developed crowdfunded vaccine against COVID-19 ACvac1.
  • With more than 20 years of experience developing an exceptionally safe and immunogenic peptide vaccine against dementia, in April 2020 Axon announced its plan to develop a novel peptide vaccine against COVID-19.
  • Michal Fresser, Chief Executive Officer of Axon said: "There is a global race for a vaccine.
  • The elderly can be overlooked by other vaccine developers in their push to find an effective vaccine quickly.

Conjugate Vaccines Market| Insights on the Crisis and the Roadmap to Recovery from COVID-19 Pandemic| Technavio

Friday, September 18, 2020 - 10:45am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200918005033/en/
    Technavio has announced its latest market research report titled Global Conjugate Vaccines Market 2020-2024 (Graphic: Business Wire)
    Get detailed insights on COVID-19 pandemic Crisis and Recovery analysis of the Conjugate Vaccines market.
  • Download free report sample
    Amid the COVID-19 Crisis, the Revaluated and Updated Conjugate Vaccines Market Report Says:
    The conjugate vaccines market will witness a Neutral and At par impact during the forecast period owing to the extensive rise of COVID-19 pandemic.
  • The conjugate vaccines market is segmented by type (multivalent conjugate vaccine and monovalent conjugate vaccine) and geography (Asia, Europe, North America, and ROW).
  • Increasing efforts for the stockpiling of conjugate vaccines has been an instrumental factor in influencing the growth of conjugate vaccines market.

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Friday, September 18, 2020 - 12:32am

Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.

Key Points: 
  • Ufovax holds an exclusive global license to the Scripps Intellectual Property covering the platform and several vaccines, including COVID-19.
  • In a publication submitted Monday, September 14 (now available on the bioRxiv preprint server ), the authors present a systematic study on rational vaccine design and evaluation of vaccine response in mice.
  • In particular, Zhu and his team propose a new spike antigen design (S2GHR2) and displayed it on several SApNPs as COVID-19 vaccine candidates.
  • In practice, we have seen similar performance from the Merck HPV Gardasil vaccine which is essentially a protein nanoparticle vaccine.

Healthvana Introduces Patient Platform to Support CDC’s COVID-19 Vaccination Playbook

Thursday, September 17, 2020 - 5:28pm

Healthvana, Inc. , the nations largest patient platform for COVID-19 and HIV test results, today announced its new mobile vaccination record and patient follow-up solution to support the CDC COVID-19 vaccination playbook released on September 16, 2020.

Key Points: 
  • Healthvana, Inc. , the nations largest patient platform for COVID-19 and HIV test results, today announced its new mobile vaccination record and patient follow-up solution to support the CDC COVID-19 vaccination playbook released on September 16, 2020.
  • Healthvana provides a single mobile platform for patients to access vaccination records, as well as ongoing SMS communications reminding them of their follow-up appointment and next steps for a successful vaccination.
  • The Healthvana platform will clearly show flu vaccinations in the same mobile dashboard as COVID-19 vaccinations.
  • Since 2015, the mobile-first patient platform has been rooted in empathy, enabling HIPAA-compliant test results to be easily and quickly distributed to patients.

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

Thursday, September 17, 2020 - 2:17pm

ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.

Key Points: 
  • ET to discuss the concept of two types of immune responses antibody vs. T Cell as well as provide an overview of the challenges of developing an effective vaccine.
  • Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
  • Tonixs lead vaccine candidate, TNX-1800*, is a live replicating, attenuated vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response.
  • Tonix is also developing TNX-2300* and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Virometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306

Thursday, September 17, 2020 - 2:00pm

All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.

Key Points: 
  • All 20 subjects received the first dose of V-306 or placebo, as planned and early clinical experience is encouraging with no adverse events reported to date.
  • We look forward to progress in the trial and will provide further updates as appropriate.
  • Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer.
  • For more information about Virometix AG please visit: https://www.virometix.com
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005406/en/